September 2025 quarter revenue rises 18.9%, profit rises 13.7% year on year
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.8 pts less than Nifty Microcap 250 and 8.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Windlas Biotech's unaudited results for the quarter ended September 30, 2025 showed revenue from operations of Rs 2,223.98 million, up 18.9% year on year, and net profit of Rs 178.00 million, up 13.7%. For the first six months, revenue rose 19.4% to Rs 4,324.88 million and profit rose 21.7% to Rs 354.64 million. Operating cash flow rose to Rs 559.24 million from Rs 296.59 million. The review raised no material concerns.
Revenue, profit and operating cash flow rose, but growth stayed below 20% for revenue and 25% for profit.